Skip to main content
. Author manuscript; available in PMC: 2017 May 1.
Published in final edited form as: Clin Cancer Res. 2016 Jan 5;22(9):2250–2260. doi: 10.1158/1078-0432.CCR-15-2276

Figure 3. Pharmacodynamic effects of GDC-0941 with fulv on MCF-7 tumors.

Figure 3

Mice were pretreated with fulv. Three days later, mice were treated with (A,C) one or (B,C) two doses of GDC-0941 as indicated. Tumors were harvested at 0–48 h after GDC-0941 treatment, and lysates were analyzed by immunoblotting using the indicated antibodies. In (A), phosphoprotein levels quantified by densitometry of immunoblots (normalized to 0 h time point) were plotted against plasma GDC-0941 levels from Fig. 2A. Data are shown as mean of triplicate tumors + SD. FL- full-length; cleav.- cleaved.